ArticleJCO global oncology2020
Evaluation of a Chip-Based, Point-of-Care, Portable, Real-Time Micro PCR Analyzer for the Detection of High-Risk Human Papillomavirus in Uterine Cervix in India.
Article in JCO global oncology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 1 synthesis or guideline pooled it, 17 citations in OpenAlex.
- Challenges in the Implementation of Human Papillomavirus Self-Sampling for Cervical Cancer Screening in India: A Systematic Review.JCO global oncology · 2023Pooled it
- Clinical Validation of Four Point-of-Care High-Risk HPV Assays, Including Two Reduced-Valency Assays, for Cervical Cancer Screening in Low-Resource Settings.International journal of cancer · 2026Article
- Integrating non-coding RNA profiling with HPV genotyping for cervical cancer risk stratification and early detection.Molecular biology reports · 2026Review
- A scoping review of evidence on routine cervical cancer screening in South Asia: investigating factors affecting adoption and implementation.Cancer causes & control : CCC · 2025Article
- CareHPV, Papanicolaou Positivity Status, and Their Association With Behavioral Risk Factors in Rural Women of Kamrup District, Assam, India.Cancer reports (Hoboken, N.J.) · 2024Article
- Assessing knowledge and awareness levels regarding cervical cancer and HPV vaccination in the Jammu regions.Iranian journal of microbiology · 2024Article
- The development, evaluation, performance, and validation of micro-PCR and extractor for the quantification of HIV-1 &-2 RNA.Scientific reports · 2024Article
- Community Screening for High-Risk Human Papilloma Virus Infection using Self-Sampling and 'Point-Of-Care' Test.Asian Pacific journal of cancer prevention : APJCP · 2024Article
- Cervical Cancer: Formulation and Implementation of Govt of India Guidelines for Screening and Management.Indian journal of gynecologic oncology · 2022Review
- TruenatThe Indian journal of medical research · 2021Article
- Assessing a chip based rapid RTPCR test for SARS CoV-2 detection (TrueNat assay): A diagnostic accuracy study.PloS one · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeCurrently available human papillomavirus (HPV) detection devices are expensive, requiring a continuous power supply, high-priced reagents, skilled laboratory personnel, and infrastructure. These make it difficult to implement primary HPV screening in high-risk (HR) populations, particularly in low-income settings such as in India. The objective of our study was to evaluate the diagnostic performance of a point-of-care, portable, battery-operated device called Truenat, which detects 4 HR HPV genotypes (16, 18, 31, and 45), as a potentially cost-effective alternative to conventional HPV diagnostic tests. PATIENTS AND
methodsThis was a single-site, blinded, cross-sectional study that evaluated the performance of the Trunat HPV-HR using cervical samples collected from nonpregnant women > 30 years old via consecutive sampling. The comparison was conducted against the Hybrid Capture 2 (HC2) method. All the positive samples were validated by 14 Real-TM Quant Kit.
resultsOf 615 cervical samples, the HR-HPV DNA test was positive in 78 women (12.7%) by HC2 and in 49 (8%) by Truenat. With the consideration of limited genotype inclusivity, the sensitivity and specificity of Truenat HPV-HR were 97.7% and 98.9%, respectively.
conclusionThe performance of Truenat HPV-HR test was comparable to that of HC2 in the 4 HPV genotypes and would be appropriate to consider for use in primary HR cervical cancer screening and particularly in low-income settings.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.